{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:13:52Z","timestamp":1789910032466,"version":"4.0.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"name":"FIDSSA-GSK"},{"name":"Discovery Foundation Academic Fellowship Award"},{"DOI":"10.13039\/100000200","name":"USAID","doi-asserted-by":"crossref","award":["#674-A-12-00020"],"award-info":[{"award-number":["#674-A-12-00020"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Research Foundation of South Africa","award":["85810"],"award-info":[{"award-number":["85810"]}]},{"name":"National Research Foundation of South Africa","award":["90729"],"award-info":[{"award-number":["90729"]}]},{"name":"Seventh"},{"name":"International Workshop on Clinical Pharmacology of TB Drugs"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1093\/jac\/dkv447","type":"journal-article","created":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T21:18:45Z","timestamp":1452287925000},"page":"1037-1040","source":"Crossref","is-referenced-by-count":60,"title":["Drug\u2013drug interactions between bedaquiline and the antiretrovirals lopinavir\/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB"],"prefix":"10.1093","volume":"71","author":[{"given":"Mishal","family":"Pandie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweetness","family":"Siwendu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conradie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Variava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,1,7]]},"reference":[{"key":"2016031409382566000_71.4.1037.1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku171"},{"key":"2016031409382566000_71.4.1037.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"2016031409382566000_71.4.1037.3","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2979"},{"key":"2016031409382566000_71.4.1037.4","unstructured":"WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach . June 2013. http:\/\/www.who.int\/hiv\/pub\/guidelines\/arv2013\/en\/ ."},{"key":"2016031409382566000_71.4.1037.5","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00003"},{"key":"2016031409382566000_71.4.1037.6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100452"},{"key":"2016031409382566000_71.4.1037.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03246-14"},{"key":"2016031409382566000_71.4.1037.8","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0944"},{"key":"2016031409382566000_71.4.1037.9","unstructured":"Center for Drug Evaluation and Research, FDA. Guidance for Industry: Bioanalytical Method Validation . September 2013. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm368107.pdf ."},{"key":"2016031409382566000_71.4.1037.10","unstructured":"EMA. Guideline on Bioanalytical Method Validation . 21 July 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf ."},{"key":"2016031409382566000_71.4.1037.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808427"},{"key":"2016031409382566000_71.4.1037.12","unstructured":"Janssen Therapeutics. SirturoTM Prescribing Information . http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/204384s000lbl.pdf ."},{"key":"2016031409382566000_71.4.1037.13","unstructured":"WHO. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis . 2014. http:\/\/www.who.int\/tb\/publications\/pmdt_companionhandbook\/en\/ ."}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/71\/4\/1037\/6993803\/dkv447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T10:16:06Z","timestamp":1503569766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkv447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,7]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,3,14]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1093\/jac\/dkv447"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv447","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,7]]}}}